ArticleJournal of virology2025
APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Occult hepatitis B virus infection.Nature reviews. Gastroenterology & hepatology · 2026Review
- Review
- hnRNPA2B1 induces HBV cccDNA degradation by recruiting APOBEC3B.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
APOBEC3 proteins (A3s) play an important role in host innate immunity against viruses and DNA mutations in cancer. A3s-induced mutations in both viral and human DNA genomes vary significantly from non-lethal mutations in viruses to localized hypermutations, such as kataegis in cancer. How A3s are regulated remains largely unknown. Since A3s exist in complexes and belong to the same family as APOBEC-1 (A1), which requires cofactors to be functional, we investigated the role of A1 cofactors and other A3 potentially associated hnRNPs on A3 mutational activity using hepatitis B virus (HBV) cellular replication as a model. We found that A1-associated cofactors and other hnRNPs were involved in A3 mutational activity regulation, and their regulatory effect was dependent on the strength of A3 association with hnRNPs with an order of A3C > 3G>3B and A1 cofactors > other hnRNPs. A1 cofactors had a strong protein interaction with A3 and significantly increased A3 mutational activity by co-expression. Endogenous gene expression knockdown by siRNA had the opposite decrease effect. Disruption of the protein interactions between A3 and hnRNPs through A3G and A3B mutagenesis decreased A3 mutational activity significantly, even to a level of near total loss, indicating that A1 cofactors and hnRNPs are required for A3 mutational activity. HBV genome-wide mutation analyses showed that A1 cofactors significantly increased A3C accessibility to HBV (-)DNA and A3C-induced mutational efficiency to generate kataegis-like hypermutation. These data demonstrate that A1 cofactors and hnRNPs are closely associated with A3s and may play an important regulatory role under physiological conditions. IMPORTANCE: As human host restriction factors, A3s play an important role against viral infections. A3s are also major mutagenic drivers of cancer. However, why A3-induced mutations vary significantly from non-lethal mutations in virus to localized hypermutations in cancer remains unknown. We found that A1 cofactor and other hnRNPs are not only associated with A3 complexes but also play important regulatory roles in A3-induced mutation activities. A1 cofactors like GRY-RBP significantly increased A3 accessibility and mutational efficiency to its single-strand DNA substrate during HBV reverse transcription to generate hypermutations. Disruption of the A3 protein association with hnRNPs by A3 mutagenesis diminished A3 mutational activity. This finding not only reveals a regulatory mechanism for A3-induced mutation but also indicates that A3-associated cellular factors can be a potential target for regulating A3-induced mutation for cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.